Cold sub-atmospheric and atmospheric pressure plasma for the treatment of Trichophyton rubrum onychomycosis: An in-vitro study.

Trichophyton rubrum atmospheric pressure plasma cold plasma onychomycosis treatment sub-atmospheric pressure plasma

Journal

Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070

Informations de publication

Date de publication:
11 2020
Historique:
received: 11 07 2020
accepted: 25 07 2020
pubmed: 31 7 2020
medline: 15 5 2021
entrez: 31 7 2020
Statut: ppublish

Résumé

Previous studies have suggested the applicability of cold atmospheric pressure plasma for the treatment of onychomycosis. Whether delivering cold plasma in sub-atmospheric pressure would be beneficial for this purpose is yet to be established. The current study aimed to evaluate efficacy of cold sub-atmospheric and atmospheric pressure plasma in Trichophyton rubrum growth inhibition. Bovine nails infected with T. rubrum were treated by a cold air plasma device, which enables utilizing plasma in sub-atmospheric pressures (Low = 100 millibar; High = 300 millibar) or atmospheric pressure. The infected foci were exposed to the plasma source directly or indirectly. Treatment with high sub-atmospheric pressure setting achieved T. rubrum growth reduction of 94.0% and 73.0%, for direct and indirect exposure to the plasma source, respectively (P < .001). Low sub-atmospheric pressure setting achieved similar T. rubrum growth reduction of 86.2% for direct exposure to the plasma source (P < .001), but only marginally significant 58.8% reduction rate for indirect exposure to the plasma source (P = .056). None statistically significant fungal growth reduction was attained with the use of atmospheric pressure setting. Cold plasma was shown to effectively inhibit T. rubrum nail growth, with sub-atmospheric pressure setting achieving better outcome than atmospheric pressure.

Identifiants

pubmed: 32729232
doi: 10.1111/dth.14084
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14084

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Lipner SR, Scher RK. Onychomycosis: clinical overview and diagnosis. J Am Acad Dermatol. 2019;80:835-851.
Milobratović D, Janković S, Vukičević J, Marinković J, Janković J, Railić Z. Quality of life in patients with toenail onychomycosis. Mycoses. 2013;56:543-551.
Shemer A. Update: medical treatment of onychomycosis. Dermatol Ther. 2012;25:582-593.
Kreijkamp-Kaspers S, Hawke K, Guo L, et al. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017;7 (7):CD010031.
Foley K, Gupta AK, Versteeg S, et al. Topical and device-based treatments for fungal infections of the toenails. Cochrane Database Syst Rev. 2020;1 (1):CD012093.
Ma W, Si C, Kasyanju Carrero LM, et al. Laser treatment for onychomycosis: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e17948.
Borges AC, Nishime TMC, de Moura Rovetta S, et al. Cold atmospheric pressure plasma jet reduces Trichophyton rubrum adherence and infection capacity. Mycopathologia. 2019;184:585-595.
Xiong Z, Roe J, Grammer TC, Graves DB. Plasma treatment of onychomycosis. Plasma Processes Polym. 2016;13:588-597.
Bulson JM, Liveris D, Derkatch I, et al. Non-thermal atmospheric plasma treatment of onychomycosis in an in vitro human nail model. Mycoses. 2020;63:225-232.
Lipner S, Friedman G, Scher R. Pilot study to evaluate a plasma device for the treatment of onychomycosis. Clin Exp Dermatol. 2017;42:295-298.
Shintani H, Sakudo A, Burke P, et al. Gas plasma sterilization of microorganisms and mechanisms of action. Exp Ther Med. 2010;1:731-738.
Scholtz V, Pazlarova J, Souskova H, Khun J, Julak J. Nonthermal plasma: a tool for decontamination and disinfection. Biotechnol Adv. 2015;33:1108-1119.
Patange A, Boehm D, Giltrap M, et al. Assessment of the disinfection capacity and eco-toxicological impact of atmospheric cold plasma for treatment of food industry effluents. Sci Total Environ. 2018;631:298-307.
Boyce JM. Modern technologies for improving cleaning and disinfection of environmental surfaces in hospitals. Antimicrob Resist Infect Control. 2016;5:10.
Handorf O, Weihe T, Bekeschus S, et al. Nonthermal plasma jet treatment negatively affects the viability and structure of Candida albicans SC5314 biofilms. Appl Environ Microbiol. 2018;84:e01163-18.
Heinlin J, Maisch T, Zimmermann JL, et al. Contact-free inactivation of Trichophyton rubrum and microsporum canis by cold atmospheric plasma treatment. Future Microbiol. 2013;8:1097-1106.
Maisch T, Shimizu T, Isbary G, et al. Contact-free inactivation of Candida albicans biofilms by cold atmospheric air plasma. Appl Environ Microbiol. 2012;78:4242-4247.
Lackmann J, Bandow JE. Inactivation of microbes and macromolecules by atmospheric-pressure plasma jets. Appl Microbiol Biotechnol. 2014;98:6205-6213.
Monti D, Saccomani L, Chetoni P, Burgalassi S, Tampucci S, Mailland F. Validation of bovine hoof slices as a model for infected human toenails: in vitro ciclopirox transungual permeation. Br J Dermatol. 2011;165:99-105.
Baraldi A, Jones S, Guesné S, et al. Human nail plate modifications induced by onychomycosis: implications for topical therapy. Pharm Res. 2015;32:1626-1633.
Johnson MJ, Go DB. Piezoelectric transformers for low-voltage generation of gas discharges and ionic winds in atmospheric air. J Appl Phys. 2015;118:243304.
Baran R, Faergemann J, Hay RJ. Superficial white onychomycosis: a syndrome with different fungal causes and paths of infection. J Am Acad Dermatol. 2007;57:879-882.
Pignata C, D'Angelo D, Basso D, et al. Low-temperature, low-pressure gas plasma application on Aspergillus brasiliensis, Escherichia coli and pistachios. J Appl Microbiol. 2014;116:1137-1148.
Ulbin-Figlewicz N, Jarmoluk A, Marycz K. Antimicrobial activity of low-pressure plasma treatment against selected foodborne bacteria and meat microbiota. Ann Microbiol. 2015;65:1537-1546.

Auteurs

Avner Shemer (A)

Department of Dermatology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Ralph Daniel (R)

University of Mississippi Medical Center, Jackson, Mississippi, USA.
University of Alabama, Birmingham, Alabama, USA.

Riad Kassem (R)

Department of Dermatology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Yuval Geffen (Y)

Department of Clinical Microbiology, Rambam Medical Center, Haifa, Israel.

Eran Galili (E)

Department of Dermatology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH